Randomized controlled trials investigating next-generation anti-obesity medications (e.g., dual GLP-1/GIP receptor agonists like tirzepatide) are needed to expand therapeutic options. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.